Recent Research Analysts’ Ratings Updates for MEDNAX (MD)

Share on StockTwits

A number of firms have modified their ratings and price targets on shares of MEDNAX (NYSE: MD) recently:

  • 2/8/2019 – MEDNAX was given a new $36.00 price target on by analysts at Mizuho. They now have a “hold” rating on the stock.
  • 2/6/2019 – MEDNAX was downgraded by analysts at Zacks Investment Research from a “hold” rating to a “sell” rating. According to Zacks, “Mednax’s shares have underperformed its industry in a year's time. Escalating expenses remain a headwind for the company. Anesthesia mix shift to Medicare is another challenge to the company. A Zacks Rank #4 and Earnings ESP of -0.24% leaves us inconclusive of a earnings surprise as it reports fourth quarter results on Feb 7. The Zacks consensus mark for the fourth quarter is pegged at 91 cents, up 4.6% year-over year. However, it is well-poised for growth on the back of a consistent rise in revenues. The company's prudent acquisitions poise it well for long-term growth.”
  • 1/28/2019 – MEDNAX was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Mednax is well-poised for growth on the back of a consistent rise in revenues driven by operational excellence, inorganic growth and strong segmental performances. The company's prudent acquisitions poise it well for long-term growth. However, its shares have underperformed its industry in a year's time. Escalating expenses remain a headwind for the company. Anesthesia mix shift to Medicare is another challenge to the company. A Zacks Rank #3 and Earnings ESP of +0.12% makes us confident of a positive earnings surprise as it reports fourth quarter results on Feb 7. The Zacks consensus mark for the fourth quarter is pegged at 91 cents, up 4.6% year-over year.”
  • 1/28/2019 – MEDNAX had its “hold” rating reaffirmed by analysts at Mizuho. They now have a $38.00 price target on the stock.
  • 1/21/2019 – MEDNAX was upgraded by analysts at Zacks Investment Research from a “sell” rating to a “hold” rating. According to Zacks, “Mednax is well-poised for growth on the back of a consistent rise in revenues. Mednax’s prudent acquisitions poise the company for long-term growth. It closed buyouts of five physician group practices in the first nine months of 2018.However, the shares have lost in a year’s time, against its industry’s gain in the same time frame. Escalating expenses remain a headwind for the company.  The rate of increase in expenses has surpassed revenue growth in the past two years and the same trend was seen in the first nine months of 2018.  Anesthesia mix shift to Medicare is another challenge to the company.”
  • 1/14/2019 – MEDNAX was upgraded by analysts at Citigroup Inc from a “neutral” rating to a “buy” rating. They now have a $34.88 price target on the stock. They noted that the move was a valuation call. They noted that the move was a valuation call.
  • 1/3/2019 – MEDNAX is now covered by analysts at Deutsche Bank AG. They set a “hold” rating and a $34.00 price target on the stock.

Shares of NYSE MD traded down $0.84 during trading hours on Monday, hitting $34.25. 32,866 shares of the company’s stock were exchanged, compared to its average volume of 771,887. MEDNAX Inc has a 1-year low of $31.68 and a 1-year high of $63.04. The company has a debt-to-equity ratio of 0.64, a quick ratio of 1.43 and a current ratio of 1.40. The stock has a market capitalization of $3.14 billion, a PE ratio of 9.76, a P/E/G ratio of 0.89 and a beta of 0.69.

MEDNAX (NYSE:MD) last posted its quarterly earnings data on Thursday, February 7th. The company reported $0.92 earnings per share for the quarter, topping the consensus estimate of $0.83 by $0.09. MEDNAX had a return on equity of 10.35% and a net margin of 7.37%. The business had revenue of $932.70 million during the quarter, compared to analysts’ expectations of $910.08 million. During the same quarter in the previous year, the firm earned $0.87 EPS. The firm’s revenue was up 2.4% compared to the same quarter last year. As a group, equities research analysts forecast that MEDNAX Inc will post 3.76 EPS for the current fiscal year.

In other MEDNAX news, insider John C. Pepia sold 2,500 shares of the company’s stock in a transaction that occurred on Tuesday, January 22nd. The stock was sold at an average price of $36.60, for a total value of $91,500.00. Following the completion of the transaction, the insider now owns 28,583 shares of the company’s stock, valued at approximately $1,046,137.80. The transaction was disclosed in a legal filing with the SEC, which is available at this hyperlink. 2.70% of the stock is currently owned by insiders.

Several hedge funds have recently added to or reduced their stakes in the company. Bank of New York Mellon Corp grew its position in MEDNAX by 4.5% during the 2nd quarter. Bank of New York Mellon Corp now owns 1,264,410 shares of the company’s stock worth $54,724,000 after acquiring an additional 54,120 shares during the last quarter. Iberiabank Corp bought a new position in MEDNAX in the 3rd quarter valued at $289,000. Bank of Montreal Can boosted its position in MEDNAX by 112.3% in the 3rd quarter. Bank of Montreal Can now owns 446,487 shares of the company’s stock valued at $20,834,000 after buying an additional 236,210 shares during the last quarter. First Hawaiian Bank bought a new position in MEDNAX in the 3rd quarter valued at $557,000. Finally, GHP Investment Advisors Inc. boosted its position in MEDNAX by 19.8% in the 3rd quarter. GHP Investment Advisors Inc. now owns 9,775 shares of the company’s stock valued at $456,000 after buying an additional 1,615 shares during the last quarter. Institutional investors own 99.76% of the company’s stock.

MEDNAX, Inc, together with its subsidiaries, provides newborn, anesthesia, maternal-fetal, radiology, pediatric cardiology, and other pediatric subspecialties physician services in the United States and Puerto Rico. It offers neonatal care services, such as clinical care to babies born prematurely or with complications within specific units at hospitals through neonatal physician subspecialists, neonatal nurse practitioners, and other pediatric clinicians; anesthesia and anesthesia subspecialty care; and acute and chronic pain management services.

See Also: Short Selling – Explanation For Shorting Stocks

Receive News & Ratings for MEDNAX Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MEDNAX Inc and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Brokerages Expect D. R. Horton Inc  to Post $0.86 EPS
Brokerages Expect D. R. Horton Inc to Post $0.86 EPS
MediBit  Achieves Market Cap of $0.00
MediBit Achieves Market Cap of $0.00
Fidelity National Information Servcs  Rating Reiterated by William Blair
Fidelity National Information Servcs Rating Reiterated by William Blair
PlayGame  Market Capitalization Tops $1.26 Million
PlayGame Market Capitalization Tops $1.26 Million
Strs Ohio Buys 1,427 Shares of CLIPPER RLTY IN/SH 144A
Strs Ohio Buys 1,427 Shares of CLIPPER RLTY IN/SH 144A
First Financial Bancorp  Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank
First Financial Bancorp Shares Bought by Zurcher Kantonalbank Zurich Cantonalbank


Leave a Reply

 
© 2006-2019 Zolmax.